Insider Buying: Compass Therapeutics, Inc. (NASDAQ:CMPX) CEO Buys 10,000 Shares of Stock

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) CEO Thomas J. Schuetz bought 10,000 shares of the business's stock in a transaction on Tuesday, May 27th. The shares were acquired at an average cost of $2.11 per share, for a total transaction of $21,100.00. Following the purchase, the chief executive officer now directly owns 6,480,825 shares in the company, valued at $13,674,540.75. This represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Compass Therapeutics Stock Up 0.9%

Shares of NASDAQ:CMPX traded up $0.02 during trading on Friday, reaching $2.14. The stock had a trading volume of 411,152 shares, compared to its average volume of 926,063. Compass Therapeutics, Inc. has a 52 week low of $0.77 and a 52 week high of $4.08. The firm has a market capitalization of $295.93 million, a price-to-earnings ratio of -5.78 and a beta of 1.40. The stock has a fifty day simple moving average of $1.89 and a two-hundred day simple moving average of $2.13.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.12) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.12). On average, analysts forecast that Compass Therapeutics, Inc. will post -0.36 EPS for the current year.

Hedge Funds Weigh In On Compass Therapeutics

A number of large investors have recently bought and sold shares of CMPX. Strs Ohio bought a new stake in Compass Therapeutics in the 1st quarter valued at $34,000. Birchview Capital LP acquired a new stake in Compass Therapeutics in the first quarter valued at about $46,000. Propel Bio Management LLC bought a new position in Compass Therapeutics in the first quarter valued at about $434,000. Walleye Trading LLC bought a new position in Compass Therapeutics in the first quarter valued at about $48,000. Finally, Walleye Capital LLC bought a new position in shares of Compass Therapeutics during the first quarter worth about $100,000. Institutional investors and hedge funds own 68.43% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently commented on CMPX. Wedbush reissued an "outperform" rating and issued a $8.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, April 1st. D. Boral Capital reissued a "buy" rating and issued a $32.00 price objective on shares of Compass Therapeutics in a research note on Monday, April 28th. Leerink Partnrs raised Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 1st. HC Wainwright reissued a "buy" rating and issued a $24.00 price objective on shares of Compass Therapeutics in a research note on Monday, April 21st. Finally, Leerink Partners raised Compass Therapeutics from a "market perform" rating to an "outperform" rating and boosted their price objective for the stock from $4.00 to $6.00 in a research note on Wednesday, April 2nd. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $13.13.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.